Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down - Here's What Happened

Key Points

• Dianthus Therapeutics shares gapped down from a previous close of $26.50 to open at $25.03 and last traded at $30.40, with a trading volume of 3,618,067 shares.
• Analysts have generally rated the stock positively, with a consensus target price of $54.00 and multiple firms adjusting target prices upwards, including Wedbush raising it from $34.00 to $42.00.
• Dianthus Therapeutics reported earnings of ($0.88) per share, missing the estimate by ($0.02), along with a significant negative net margin of 2,364.56%.

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $26.50, but opened at $25.03. Dianthus Therapeutics shares last traded at $30.40, with a volume of 3,618,067 shares traded.

Analyst Ratings Changes

Several analysts have weighed in on DNTH shares. Wedbush boosted their target price on shares of Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an "outperform" rating in a research report on Thursday, August 21st. Robert W. Baird decreased their target price on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. William Blair assumed coverage on Dianthus Therapeutics in a report on Wednesday, July 2nd. They set an "outperform" rating on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday. Seven research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of "Buy" and a consensus target price of $54.00.

Dianthus Therapeutics Price Performance

The firm has a market cap of $1.02 billion, a price-to-earnings ratio of -9.82 and a beta of 1.46. The company's 50 day simple moving average is $21.27 and its 200 day simple moving average is $20.03.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.87 million. As a group, analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

Large investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD lifted its stake in shares of Dianthus Therapeutics by 21.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,468 shares of the company's stock valued at $207,000 after buying an additional 1,647 shares in the last quarter. Northern Trust Corp lifted its position in shares of Dianthus Therapeutics by 21.2% during the fourth quarter. Northern Trust Corp now owns 245,523 shares of the company's stock valued at $5,352,000 after buying an additional 42,923 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Dianthus Therapeutics during the 4th quarter valued at approximately $59,000. Cubist Systematic Strategies LLC increased its position in shares of Dianthus Therapeutics by 9.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 54,766 shares of the company's stock worth $1,194,000 after purchasing an additional 4,518 shares during the last quarter. Finally, Deutsche Bank AG lifted its stake in Dianthus Therapeutics by 55.9% in the fourth quarter. Deutsche Bank AG now owns 20,011 shares of the company's stock valued at $436,000 after buying an additional 7,179 shares during the last quarter. Institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.